Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) FCF Margin (2016 - 2025)

Historic FCF Margin for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to 6.4%.

  • Integra Lifesciences Holdings' FCF Margin rose 82800.0% to 6.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.27%, marking a year-over-year decrease of 27100.0%. This contributed to the annual value of 1.55% for FY2024, which is 31900.0% down from last year.
  • As of Q3 2025, Integra Lifesciences Holdings' FCF Margin stood at 6.4%, which was up 82800.0% from 2.7% recorded in Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' FCF Margin peaked at 21.71% during Q2 2021, and registered a low of 10.5% during Q1 2025.
  • Moreover, its 5-year median value for FCF Margin was 6.4% (2025), whereas its average is 7.54%.
  • As far as peak fluctuations go, Integra Lifesciences Holdings' FCF Margin soared by 161200bps in 2021, and later crashed by -117800bps in 2023.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' FCF Margin stood at 10.32% in 2021, then surged by 73bps to 17.81% in 2022, then tumbled by -52bps to 8.62% in 2023, then tumbled by -45bps to 4.78% in 2024, then soared by 34bps to 6.4% in 2025.
  • Its FCF Margin was 6.4% in Q3 2025, compared to 2.7% in Q2 2025 and 10.5% in Q1 2025.